380 results on '"MacGrogan, Gaëtan"'
Search Results
2. Mechanistic modeling of metastatic relapse in early breast cancer to investigate the biological impact of prognostic biomarkers
3. PTEN alterations in sporadic and BRCA1-associated triple negative breast carcinomas
4. Impact of the COVID-19 lockdown in France on the diagnosis and staging of breast cancers in a tertiary cancer centre
5. Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study
6. Mise à jour 2021 des recommandations du GEFPICS pour l’évaluation du statut HER2 dans les cancers infiltrants du sein en France
7. Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations
8. Solid-type adenoid cystic carcinoma of the breast, a distinct molecular entity enriched in NOTCH and CREBBP mutations
9. Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study
10. Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort
11. Terahertz refractive index-based morphological dilation for breast carcinoma delineation
12. Recommandations du GEFPICS pour la prise en charge des prélèvements dans le cadre du traitement néoadjuvant du cancer du sein
13. Medullary Breast Carcinoma, a Triple-Negative Breast Cancer Associated with BCLG Overexpression
14. Solid papillary carcinoma with reverse polarity of the breast harbors specific morphologic, immunohistochemical and molecular profile in comparison with other benign or malignant papillary lesions of the breast: a comparative study of 9 additional cases
15. Lésions frontières en pathologie mammaire à fort risque de surdiagnostic : lesquelles ? Double lecture anatomopathologique, une nécessité ?
16. Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors
17. Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy
18. Alternative PDGFD rearrangements in dermatofibrosarcomas protuberans without PDGFB fusions
19. Efficacy of antiandrogens in androgen receptor-positive triple-negative metastatic breast cancer: Real-life data
20. SOX10, GATA3, GCDFP15, Androgen Receptor, and Mammaglobin for the Differential Diagnosis Between Triple-negative Breast Cancer and TTF1-negative Lung Adenocarcinoma
21. Supplementary Data Table from The Nanocind Signature Is an Independent Prognosticator of Recurrence and Death in Uterine Leiomyosarcomas
22. Data from CD95L Cell Surface Cleavage Triggers a Prometastatic Signaling Pathway in Triple-Negative Breast Cancer
23. Supplementary Figures 1 - 5 from CD95L Cell Surface Cleavage Triggers a Prometastatic Signaling Pathway in Triple-Negative Breast Cancer
24. Supplementary Methods from CD95L Cell Surface Cleavage Triggers a Prometastatic Signaling Pathway in Triple-Negative Breast Cancer
25. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group
26. Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions
27. Lésions « à risque » et frontières
28. Utiliser une signature moléculaire pour la prise en charge d'une patiente atteinte d'un cancer du sein : la quête du Graal…
29. Surgery following neoadjuvant chemotherapy for HER2-positive locally advanced breast cancer. Time to reconsider the standard attitude
30. Neoadjuvant endocrine treatment in breast cancer: analysis of daily practice in large cancer center to facilitate decision making
31. Mise à jour 2014 des recommandations du GEFPICS pour l’évaluation du statut HER2 dans les cancers du sein en France
32. Recommandations du GEFPICS concernant la phase pré-analytique pour l’évaluation de HER2 et des récepteurs hormonaux dans le cancer du sein : mise à jour 2014
33. Le cancer du sein triple-négatif. Le triple-négatif est fréquent chez les patientes mutées : comment ne pas le rater ? Comment le caractériser ? De manière plus générale, l’imagerie peut-elle orienter vers le diagnostic histologique ?
34. YWHAE rearrangement identified by FISH and RT-PCR in endometrial stromal sarcomas: genetic and pathological correlations
35. Comprehensive prognostic analysis in breast cancer integrating clinical, tumoral, micro-environmental and immunohistochemical criteria
36. The Role of Sentinel Lymph Node Biopsy and Factors Associated with Invasion in Extensive DCIS of the Breast Treated by Mastectomy: The Cinnamome Prospective Multicenter Study
37. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials
38. Accuracy of HER2 status determination on breast core-needle biopsies (immunohistochemistry, FISH, CISH and SISH vs FISH)
39. Neoadjuvant chemotherapy and radiotherapy for locally advanced breast cancer: Safety and efficacy of reverse sequence compared to standard technique?
40. All atypia diagnosed at stereotactic vacuum-assisted breast biopsy do not need surgical excision
41. L’examen cytologique a-t-il encore sa place dans l’analyse extemporanée du ganglion sentinelle dans le cancer du sein ?
42. Scanning point terahertz source microscopy of unstained comedo ductal carcinoma in situ
43. Liste des auteurs
44. Le carcinome adénoïde kystique du sein : étude clinique, histologique, immunohistochimique et revue de la littérature
45. Abstract P2-07-10: Germline BRCA screening for locally advanced breast cancer treated by neoadjuvant chemotherapy: Defining a subgroup with high rate of mutation and local relapses
46. Scanning point terahertz source microscopy of unstained comedo ductal carcinoma in situ
47. Prediction of HER2 gene status in Her2 2+ invasive breast cancer: a study of 108 cases comparing ASCO/CAP and FDA recommendations
48. D2-40 in breast cancer: should we detect more vascular emboli?
49. Impact of the COVID-19 lockdown in France on the diagnosis and staging of breast cancers in a tertiary cancer centre
50. Breast hamartoma: reassessment of an under‐recognised breast lesion
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.